Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Subarachnoid HemorrhageHypertension
Interventions
DRUG

Clevidipine butyrate injectable emulsion

Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.

Trial Locations (1)

48202

Henry Ford Hospital, Detroit

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Medicines Company

INDUSTRY

lead

Henry Ford Health System

OTHER